Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: Evidence and arguments

Acta Psychiatrica Scandinavica

Volumn 103, Issue 5, 2001, Pages 335-346

  Bosveld Van Haandel, L J M ^a   Slooff, C J ^a   Van Den Bosch, R J ^b  

^a Mental Health Centre Drenthe   (Netherlands)

^b NONE

Author keywords

Antipsychotic agents; Long term care; Recurrence; Schizophrenia; Treatment outcome

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DECISION MAKING; EVIDENCE-BASED MEDICINE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035020994     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2001.00089.x     Document Type: Review

References (85)

1. 1. Green Jf, King DJ. Cognitive functioning in schizophrenia. Effects of drug treatments. CNS Drugs 1996;6:382-398.
2. 2. Weinberger DR, Gallhofer B. Cognitive function in schizophrenia. Int Clin Psychopharmacol 1997;12(Suppl. 4); S29-S36.
3. 3. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-228.
4. 4. Dutch Schizophrenia Foundation. Consensus document. The Netherlands: Schizophrenia Foundation, 1996.
5. 5. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl. 4):S1-S63.
6. 6. McEvoy JP, Scheifler PL, Frances A, eds. The expert consensus guideline series. Treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(Suppl. 11).
7. 7. Kissling W, ed. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer-Verlag, 1989.
8. 8. Peuskens J. Good medical practice in antipsychotic pharmacotherapy. Int Clin Psychopharmacol 1998;13(Suppl. 3): S35-S41.
9. 9. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 1998;24:75-85.
10. 10. Sartorius N, Gulbinat W, Harrison G, Laska G, Siegel C. Long-term follow-up of schizophrenia in 16 countries: a description of the International Study of Schizophrenia conducted by the World Health Organization. Soc Psychiatry Psychiatr Epidemiol 1996;31:249-258.
11. 11. Asselbergs L. Het sociale functioneren van schizofreniepatiënten. Een deelonderzoek van het Psychose Preventie Project. Maanbl Geest Volksgez 1990;1:3-17.
12. 12. Johnson DAW. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 1979;135:524-530.
13. 13. Robinson D, Woerner MG, Ma J et al. Predictors of relapse following response from a first episode of schizophrenia of schizoaffective disorder. Arch Gen Psychiatry 1999;56: 241-247.
14. 14. Johnson DAW. Observations on the use of depot neuroleptics in schizophrenia. In Casey DE, Christensen AV, eds. Psychopharmacology: current trends. Berlin: Springer Verlag, 1988:62-73.
15. 15. Huber G, Gross G, Schüttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980;6: 592-605.
16. 16. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-188.
17. 17. Zhang-Wong J, Beiser M, Bean G, Iacono WG. Five-year course of schizophreniform disorder. Psychiatr Res 1995;59: 109-117.
18. 18. Doering S, Müller E, Köpcke W et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24:87-98.
19. 19. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54(Suppl. 3):S13-S17.
20. 20. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999;60(Suppl. 3):S3-S7.
21. 21. Mueser KT, Bellack AS, Morrison RL, Wixted JT. Social competence in schizophrenia: premorbid adjustment, social skill, and domains of functioning. J Psychiatr Res 1990;24: 51-63.
22. 22. Childers SE, Harding CM. Gender, premorbid social functioning, and long-term outcome in DSM-III schizophrenia. Schizophr Bull 1990;16:309-318.
23. 23. Johnstone EC, MacMillan JF, Frith CD, Benn DK, Crow TJ. Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry 1990;157: 182-189.
24. 24. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330.
25. 25. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 1998;18(Suppl. 1):S12-S19.
26. 26. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222.
27. 27. Tollefson GD. Cognitive function in schizophrenic patients. J Clin Psychiatry 1996;57(Suppl. 11):S31-S39.
28. 28. Schuldberg D, Quinlan DM, Glazer W. Positive and negative symptoms and adjustment in severely mentally ill outpatients. Psychiatr Res 1999;85:177-188.
29. 29. Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998;13(Suppl. 3): S21-S26.
30. 30. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C, Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980:6:70-87.
31. 31. Davis JM, Janicak PG, Singla A, Sharma RP. Antipsychotic drugs and their side-effects, ch. 12. Maintenance antipsychotic medication. Academic Press Limited, 1993;183-203.
32. 32. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52: 189-192.
33. 33. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982;39:70-73.
34. 34. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. 2. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-127.
35. 35. Lieberman J, Darlene J, Geisler S et al. Time course and biologic correlates of treatment response in first-episodic schizophrenia. Arch Gen Psychiatry 1993;50:369-376.
36. 36. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32:243-250.
37. 37. Viguera AC, Baldessarini RJ, Hegarty JD, Van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49-55.
38. 38. Johnson DAW. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 1976;53: 298-301.
39. 39. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976;37:494-500.
40. 40. Dencker SJ, Lepp M, Malm U. Do schizophrenics will adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatr Scand 1980;61(Suppl. 279): S64-S76.
41. 41. Levine J, Schooler NR, Severe J et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Adv Biochem Psychopharmacol 1980;24:483-493.
42. 42. Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 1981;64:65-84.
43. 43. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs? Br J Psychiatry 1981;138;490-494.
44. 44. Odejide OA, Aderaounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry 1982;43:195-196.
45. 45. Dencker SJ, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 1986;73:181-185.
46. 46. Linszen D. Recent onset schizophrenic disorders: outcome, prognosis and treatment. Thesis. Ridderkerk; Ridderprint BV, 1993:113-122.
47. 47. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255.
48. 48. Weiden P, Rapkin B, Mott T et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310.
49. 49. Kane JM. Compliance issues in outpatient treatment. J Clin Psychopharmacol 1985;5:22-27.
50. 50. Angermeyer MC, Matschinger H. Lay beliefs about schizophrenic disorder: the results of a population survey in Germany. Acta Psychiatr Scand 1994;89(Suppl. 382): S39-S45.
51. 51. Kemp R, David A. Compliance therapy; an intervention targeting insight and treatment adherence in psychotic patients. Behav Cogn Psychother 1996;24:331-350.
52. 52. Kemp R, Kirov G, Everitt B, Hayward P, David D. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998;172:413-419.
53. 53. Liberman RP, MacKain S, Blackwell G, Corrigan P. Medication management. Hosp Community Psychiatry 1990;41:1145-1146.
54. 54. Eckman T, Liberman RP, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol 1990;10:33-38.
55. 55. Goldstein MJ, Ridnick EH, Evan JR, May PRA, Steinberg MR. Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry 1978;35:1169-1177.
56. 56. Kane JM, Rifkin A, Woerner M et al. Low-dose neuroleptic treatment of outpatients. 1. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893-896.
57. 57. Lehman HE, Wilson WH, Deutsch M. Minimal maintenance medication: effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Comp Psychiatry 1983;24:293-303.
58. 58. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 1986;47:30-33.
59. 59. Marder Sr, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA. Low-and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987;44:518-521.
60. 60. Johnson DAW, Ludlow JM, Street K, Taylor RDW. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised outpatients with schizophrenia. Br J Psychiatry 1987;151:634-638.
61. 61. Hogarty GE, McEvoy JP, Munetz M et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 1988;45:797-805.
62. 62. Davis JM, Kane JM, Marder S et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993;54(Suppl. 3): S24-S30.
63. 63. Schooler NR, Keith SJ, Severe JB et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-463.
64. 64. Carpenter WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999;156:412-418.
65. 65. Lieberman JA. Focus on schizophrenia. Global Medical Conference, February 1998, Switzerland.
66. 66. Carpenter Jr WT, Hanlon TE, Heinrichs DW et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148.
67. 67. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. Br Med J 1989;298:985-990.
68. 68. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. Br Med J 1990;301:837-842.
69. 69. Herz MI, Glazer WM, Mostert MA et al. Intermittent vs maintenance medication in schizophrenia, two-year results. Arch Gen Psychiatry 1991;48:333-339.
70. 70. Pietzcker A, Gaebel W, Köpcke W et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia-2-year results of a german multicenter study. J Psychiatr Res 1993;27:321-339.
71. 71. Gaebel W. Intermittent medication - an alternative? Acta Psychiatr Scand 1994;89(Suppl. 382):S33-S38.
72. 72. Van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao extrapyramidal syndromes study III. Am J psychiatry 1998:155:565-567.
73. 73. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. The third generation of progress. New York: Raven Press, 1987: 1411-1419.
74. 74. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV, eds. Psychopharmacology: current trends. Berlin: Springer Verlag, 1988:74-93.
75. 75. Arato M, O'Connor R, Meltzer H, Bradbury J. Ziprasidone: efficacy in the prevention of relapse and in the longterm treatment of negative symptoms of chronic schizophrenia. Neuropsychopharmacology 1997;7(Suppl. 2);S214.
76. 76. Speller JC, Barnes TRE, Curson DA, Pantalis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Br J Psychiatry 1997;171:564-568.
77. 77. Daniel DG, Wozniak P, Mack RJ, McCarthy BG and the Sertindole Study Group. Psychotic disorders. Psychopharmacol Bull 1998;34:61-69.
78. 78. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505.
79. 79. Csernansky J, Okamoto A, Brecher M. Risperidone vs haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: a long-term double-blind comparison. Presented at the 152th Annual Meeting of the American Psychiatric Association, Washington, May 15-20, 1999.
80. 80. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res 1999;35:S87-S92.
81. 81. Leucht S, Pischel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophr Res 1999;35:51-68.
82. 82. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harvard Rev Psychiatry 1997;4:255-271.
83. 83. Campbel M, Young PI, Bateman DN, Smith JM, Thomas SHL. The use of anti-psychotics in the management of schizophrenia. Br J Clin Pharmacol 1999;47:13-22.
84. 84. Dequardo Jr, Tandon R. Do atypical antipsychotic medications favourably alter the long-term course of schizophrenia? J Psychaitr Res 1998;32:229-242.
85. 85. Dawkins K, Lieberman JA, Lebowitz BD, Hsiao JK. Antipsychotics: past and future. National Institute of Mental Health, Division of Services and Intervention Research Workshop, July 14, 1998. Schizophr Bull 1999; 25:395-405.